



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Nexturastat A

Cat. No.:	HY-16699
CAS No.:	1403783-31-2
Molecular Formula:	C ₁₉ H ₂₃ N ₃ O ₃
Molecular Weight:	341.4
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 56 mg/mL (164.03 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.9291 mL	14.6456 mL	29.2912 mL
	5 mM		0.5858 mL	2.9291 mL	5.8582 mL
	10 mM		0.2929 mL	1.4646 mL	2.9291 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Nexturastat A is a potent, selective HDAC6 inhibitor. Nexturastat A has inhibitory for HDAC6 with an IC₅₀ of 5 nM. Nexturastat A can be used for the research of multiple myeloma (MM)^{[1][2]}.

IC₅₀ & Target

HDAC6 5.02 nM (IC ₅₀)	HDAC8 0.954 μM (IC ₅₀)	HDAC1 3.02 μM (IC ₅₀)	HDAC7 4.46 μM (IC ₅₀)
HDAC11	HDAC3	HDAC9	HDAC2

	5.14 μM (IC ₅₀)	6.68 μM (IC ₅₀)	6.72 μM (IC ₅₀)	6.92 μM (IC ₅₀)
	HDAC10 7.57 μM (IC ₅₀)	HDAC4 9.39 μM (IC ₅₀)	HDAC5 11.7 μM (IC ₅₀)	
In Vitro	Nexturastat A (5 g) has inhibitory for HDAC6 with IC ₅₀ values of 0.005 μM ^[1] . Nexturastat A (0-10 μM ; 24 h) has substrate selectivity for HDAC6 ^[1] . Nexturastat A has antiproliferative activity against B16 murine melanoma cells with IC ₅₀ values of 14.3 μM ^[1] . Nexturastat A (NexA) (0-40 μM ; 48 h) suppresses viability and induced G1 phase arrest of human MM cells ^[2] . Nexturastat A (0, 30, 40 μM ; 48 h) promotes apoptosis of MM cells via transcriptional activation of the p21 promoter ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Western Blot Analysis ^[1]			
	Cell Line:	B16 murine melanoma cells		
	Concentration:	0-10 μM		
	Incubation Time:	24 h		
	Result:	Increased the level of acetyl α -tubulin levels in a dose-dependent.		
	Cell Viability Assay ^[2]			
	Cell Line:	RPMI-8226 and U266 cells		
	Concentration:	0-40 μM		
	Incubation Time:	48 h		
	Result:	Impaired multiple myeloma (MM) cells viability in a dose- and time-dependent manner.		
	Apoptosis Analysis ^[2]			
	Cell Line:	RPMI-8226 and U266 cells		
	Concentration:	0, 30, 40 μM		
	Incubation Time:	48 h		
	Result:	Induced cell apoptosis in human MM cells.		
RT-PCR ^[2]				
Cell Line:	RPMI-8226 and U266 cells			
Concentration:	30 μM			
Incubation Time:	48 h			
Result:	Increased the levels of p21 mRNA in RPMI-8226 and U266 cells.			
In Vivo	Nexturastat A (NexA) (every two days, 20 days) inhibits tumor growth in murine xenograft models of MM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

- Cell Death Dis. 2022 Aug 17;13(8):717.
- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Xiaoyang Sun, et al. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci Rep. 2019 Mar 22;39(3):BSR20181916.

[2]. Bergman JA, et al. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA